Treatment response score to glatiramer acetate or interferon beta-1a

Comparison of switch to fingolimod or interferon beta/glatiramer acetate in active multiple sclerosis.

IMPORTANCE After multiple sclerosis (MS) relapse while a patient is receiving an injectable disease-modifying drug, many physicians advocate therapy switch, but the relative effectiveness of different switch decisions is often uncertain. OBJECTIVE To compare the effect of the oral immunomodulator fingolimod with that of all injectable immunomodulators (interferons or glatiramer acetate) on re...

Clinical response to interferon beta and glatiramer acetate in multiple sclerosis patients: a Brazilian cohort.

INTRODUCTION Many patients with multiple sclerosis (MS) are currently receiving treatment with interferon beta (IFNb) and glatiramer acetate (GA). Identifying nonresponders patients is important to define therapy strategies. Several criteria for treatment response to IFNb and GA have been proposed. OBJECTIVE It was to investigate the response to treatment with IFNb-1a, IFNb-1b and GA among re...

Glatiramer acetate treatment negatively regulates type I interferon signaling

OBJECTIVE Glatiramer acetate (GA; Copaxone), a disease-modifying therapy for multiple sclerosis (MS), promotes development of anti-inflammatory (M2, type II) monocytes that can direct differentiation of regulatory T cells. We investigated the innate immune signaling pathways that participate in GA-mediated M2 monocyte polarization. METHODS Monocytes were isolated from myeloid differentiation ...

Multiple sclerosis-associated fatigue during disease-modifying treatment with natalizumab, interferon-beta and glatiramer acetate.

Differential glatiramer acetate treatment persistence in treatment-naive patients compared to patients previously treated with interferon

BACKGROUND In the treatment of multiple sclerosis, a change of therapy is considered after treatment failure or adverse events. Although disease modifying drugs' (DMD) efficacy and side effects have been fully analysed in clinical trials, the effects of previous therapy use are less well studied. We aimed to study medication persistence with glatiramer acetate in treatment-naive patients and in...